Immune Cell Profiling Predicts TNF Inhibitor Response in IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) using TNF-alpha inhibitors are hindered by high costs, systemic side effects, and the inability to predict patient response, leading to inefficient use and potential adverse reactions.
Innovation Solution
Analyzing the frequency of specific immune cell subpopulations in tissue biopsies, such as activated monocytes M1 and M2 macrophages, memory B cells, neutrophils, and CD8+ T cells, to predict responsiveness to TNF-alpha inhibitors, enabling personalized treatment selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNF-alpha inhibitors are used to treat IBD, then inflammation is reduced and mucosal healing is achieved, but response is heterogeneous with only 60% of patients showing clear improvement
Solution Approach 1:
The patent applies preliminary action by performing immune cell profiling on colon biopsies before initiating TNF-alpha inhibitor treatment. This pre-treatment assessment identifies patients likely to respond versus non-responders, enabling personalized treatment selection before exposure to potentially ineffective therapy and its associated risks.
Solution Approach 2:
The patent uses immune cell proportions in colon tissue as an intermediary biomarker to predict treatment response. Specifically, the ratio of infiltrating immune cells (such as lymphocytes, plasma cells, and macrophages) serves as a mediator between patient characteristics and treatment outcome, providing an objective measure to guide therapy selection.
2Reliability
If anti-TNF biologics are prescribed, then treatment efficacy is achieved in responders, but high costs and systemic side effects occur
Solution Approach 1:
The patent applies preliminary anti-action by identifying and preventing non-response before it occurs. Through pre-treatment immune cell profiling, patients unlikely to respond are identified and steered toward alternative therapies, thereby preventing the harmful effects of ineffective treatment including infections, anaphylaxis-like reactions, auto-antibody induction, and unnecessary financial burden.
Solution Approach 2:
The patent enables self-service by allowing the patient's own immune cell profile to predict treatment response. The biomarker assay uses the patient's tissue characteristics to inform treatment decisions, creating a self-referential system where the body's own biology guides therapeutic selection.
3Loss of time
If anti-TNF treatment is initiated without prediction, then early treatment of responders is enabled, but non-responders undergo unnecessary treatment trial period
Solution Approach 1:
The patent performs preliminary immune cell profiling before treatment initiation to predict response. This advance assessment eliminates the need for an 8-14 week trial period in non-responders, as treatment decisions are made based on pre-established biomarker thresholds rather than delayed clinical assessment.
Solution Approach 2:
The patent replaces the mechanical/clinical monitoring system (endoscopic and histologic assessment over 8-14 weeks) with a molecular biomarker-based prediction system. Instead of relying on time-consuming clinical trials and physical examinations, the invention uses immune cell proportion measurements to immediately predict treatment response.
Data Source
AI summary
Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.